193 related articles for article (PubMed ID: 35958552)
21. Case report: Autoimmune nodopathy with concurrent serum and CSF IgG4 anti-neurofascin 155 antibodies.
Wang W; Liu L; Zhang M; Yang R; Liu D; Yang S; Meng Q
Front Immunol; 2022; 13():1028282. PubMed ID: 36248836
[TBL] [Abstract][Full Text] [Related]
22. Neuromyelitis optica spectrum disorder with increased aquaporin-4 microparticles prior to autoantibodies in cerebrospinal fluid: a case report.
Bejerot S; Hesselmark E; Mobarrez F; Wallén H; Hietala MA; Nybom R; Wetterberg L
J Med Case Rep; 2019 Jan; 13(1):27. PubMed ID: 30696485
[TBL] [Abstract][Full Text] [Related]
23. Successful autologous hematopoietic stem cell transplantation in a refractory anti-Caspr1 antibody nodopathy.
Afanasiev V; Tsouni P; Kuntzer T; Cairoli A; Delmont E; Vallat JM; Devaux J; Théaudin M
J Peripher Nerv Syst; 2024 Mar; 29(1):116-119. PubMed ID: 38123899
[TBL] [Abstract][Full Text] [Related]
24. 2 grams versus 1 gram rituximab as maintenance schedule in multiple sclerosis, neuromyelitis optica spectrum disorders and related diseases: What B-cell repopulation data tell us.
Rual C; Biotti D; Lepine Z; Delourme A; Berre JL; Treiner E; Ciron J
Mult Scler Relat Disord; 2023 Mar; 71():104563. PubMed ID: 36791624
[TBL] [Abstract][Full Text] [Related]
25. Clinical evaluation of rituximab treatment for neuromyelitis optica.
Fernández-Megía MJ; Casanova-Estruch B; Pérez-Miralles F; Ruiz-Ramos J; Alcalá-Vicente C; Poveda-Andrés JL
Neurologia; 2015 Oct; 30(8):461-4. PubMed ID: 25444411
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and safety of rituximab in autoimmune nodopathy: a single-center cohort study.
Liu B; Hu J; Sun C; Qiao K; Xi J; Zheng Y; Sun J; Luo S; Zhao Y; Lu J; Lin J; Zhao C
J Neurol; 2023 Sep; 270(9):4288-4295. PubMed ID: 37195346
[TBL] [Abstract][Full Text] [Related]
28. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy.
Querol L; Nogales-Gadea G; Rojas-Garcia R; Martinez-Hernandez E; Diaz-Manera J; Suárez-Calvet X; Navas M; Araque J; Gallardo E; Illa I
Ann Neurol; 2013 Mar; 73(3):370-80. PubMed ID: 23280477
[TBL] [Abstract][Full Text] [Related]
29. Case report: Anti-CNTN1 antibody-associated nodopathies disease with asymmetric onset.
Li Q; Chen Q; Zhang T; Xu Y; Kan Y; Zhang J
Front Neurol; 2023; 14():1124540. PubMed ID: 36970505
[TBL] [Abstract][Full Text] [Related]
30. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.
Flanagan EP; Levy M; Katz E; Cimbora D; Drappa J; Mealy MA; She D; Cree BAC
Mult Scler Relat Disord; 2022 Jan; 57():103352. PubMed ID: 35158461
[TBL] [Abstract][Full Text] [Related]
31. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
[TBL] [Abstract][Full Text] [Related]
32. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
33. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
Cohen M; Romero G; Bas J; Ticchioni M; Rosenthal M; Lacroix R; Brunet C; Rico A; Pelletier J; Audoin B; Lebrun C
J Neurol Sci; 2017 Feb; 373():335-338. PubMed ID: 28131216
[TBL] [Abstract][Full Text] [Related]
34. Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration.
Tahara M; Oeda T; Okada K; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
Mult Scler Relat Disord; 2022 Apr; 60():103730. PubMed ID: 35287025
[TBL] [Abstract][Full Text] [Related]
35. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M
Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
[TBL] [Abstract][Full Text] [Related]
36. [Autoimmune Nodopathy].
Ogata H
Brain Nerve; 2024 May; 76(5):534-539. PubMed ID: 38741493
[TBL] [Abstract][Full Text] [Related]
37. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels.
Nakashima I; Takahashi T; Cree BA; Kim HJ; Suzuki C; Genain CP; Vincent T; Fujihara K; Itoyama Y; Bar-Or A
J Clin Neurosci; 2011 Jul; 18(7):997-8. PubMed ID: 21565508
[TBL] [Abstract][Full Text] [Related]
38. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
[TBL] [Abstract][Full Text] [Related]
39. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.
Zhou Y; Yan C; Gu X; Zhou L; Lu J; Zhu W; Huan X; Luo S; Zhong H; Lin J; Lu J; Zhao C; Xi J
Muscle Nerve; 2021 Jun; 63(6):824-830. PubMed ID: 33745138
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Wang Y; Chang H; Zhang X; Yin L
Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
